SM
Samuel Bates Martin
SVP and CFO

Samuel Bates Martin insider trades: Celldex Therapeutics (CLDX) stock buys and sales

SVP and CFO, Celldex Therapeutics Last trade Jun 14, 2024 18 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
7
Open-market trades
since 2020
1
Company
last trade 2024

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Samuel reports to the SEC

Open-market buys and sales

7 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jun 14, 2024CLDX↓ Sell$608K
May 30, 2024CLDX↓ Sell$1.2M
Aug 12, 2022CLDX↓ Sell$730K
Dec 23, 2021CLDX↓ Sell10b5-1$399K
Nov 15, 2021CLDX↓ Sell10b5-1$414K
Aug 10, 2021CLDX↓ Sell$124K
Jun 9, 2020CLDX↑ Buy$30K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other CLDX insiders

Open-market trades in the last 12 months

About Samuel Bates Martin's insider trades

Samuel Bates Martin is SVP and CFO at Celldex Therapeutics (CLDX). Since Jun 9, 2020, Samuel has reported 1 open-market purchase worth $30K and 6 sales worth $3.5M on SEC Form 4. There have been no open-market trades in the last 12 months.

2 sales (23% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.

Their filings also include grants and awards (9 filings), option exercises (8 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CLDX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.